M (continued)
- MultiHance
- MultiHance
- multikinase inhibitor AT9283
- multikinase inhibitor SAR103168
- multimodality treatment
- multiple endocrine adenomatosis
- multiple endocrine neoplasia syndrome
- multiple endocrine neoplasia type 1 syndrome
- multiple hamartoma syndrome
- multiple myeloma
- multiple sclerosis
- multiplicity
- MultiStem
- multitargeted receptor tyrosine kinase inhibitor ABT-869
- multitargeted receptor tyrosine kinase inhibitor MP470
- multitargeted tyrosine kinase inhibitor AP24534
- multitargeted tyrosine kinase inhibitor BIBF 1120
- multitargeted tyrosine kinase inhibitor DCC-2036
- multitargeted tyrosine kinase inhibitor JNJ-26483327
- multitargeted tyrosine kinase inhibitor MGCD265
M (continued)
- multitargeted tyrosine kinase inhibitor PLX3397
- multivitamin
- mung bean
- muramyl tripeptide phosphatidylethanolamine
- mureletecan
- murine TYRP2 plasmid DNA vaccine
- muromonab-CD3
- muscle wasting
- musculoskeletal
- MUSE
- music therapy
- Mustargen
- mustine
- mutagen
- Mutamycin
- mutant p53 peptide pulsed dendritic cell vaccine
- mutate
- mutation
- mutation carrier
- MVA-FCU1 TG4023